# Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis

> **NCT00836485** · PHASE2 · COMPLETED · sponsor: **Senju USA, Inc.** · enrollment: 122 (actual)

## Conditions studied

- Allergic Conjunctivitis

## Interventions

- **DRUG:** Ketotifen 4.0% Patch
- **DRUG:** Placebo
- **DRUG:** Olopatadine 0.2%
- **DRUG:** Artificial tears

## Key facts

- **NCT ID:** NCT00836485
- **Lead sponsor:** Senju USA, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-02
- **Primary completion:** 2009-03
- **Final completion:** 2009-03
- **Target enrollment:** 122 (ACTUAL)
- **Last updated:** 2023-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00836485

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00836485, "Evaluation of the Safety and Efficacy of Ketotifen 4.0% Patch as Compared to Placebo Patch, Olopatadine 0.2% Ophthalmic Solution, and Artificial Tears in the Conjunctival Allergen Challenge (CAC) Model of Acute Allergic Conjunctivitis". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00836485. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*